VERITAC-2: A Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer

Authors

Erika P Hamilton, Sarah Cannon Research Institute
Cynthia Ma, Washington University School of Medicine in St. Louis
Michelino De Laurentiis, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Hiroji Iwata, Nagoya City University
Sara A Hurvitz, University of Washington
Seth A Wander, Harvard University
Michael Danso, Virginia Oncology Associates
Dongrui R Lu, Pfizer, Inc.
Julia Perkins Smith, Pfizer, Inc.
Yuan Liu, Pfizer, Inc.
Lana Tran, Pfizer, Inc.
Sibyl Anderson, Arvinas Operations, Inc.
Mario Campone, Institut de Cancérologie de l'Ouest Angers-Nantes

Journal

Future Oncology

Publication Date

7-29-2024

Volume

20

Issue

32

First Page

2447

Last Page

2455

Document Type

Open Access Publication

DOI

10.1080/14796694.2024.2377530

Rights and Permissions

Hamilton EP, Ma C, De Laurentiis M, Iwata H, Hurvitz SA, Wander SA, Danso M, Lu DR, Perkins Smith J, Liu Y, Tran L, Anderson S, Campone M. VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future Oncol. 2024;20(32):2447-2455. doi: 10.1080/14796694.2024.2377530. © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

Recommended Citation

Hamilton, Erika P; Ma, Cynthia; De Laurentiis, Michelino; Iwata, Hiroji; Hurvitz, Sara A; Wander, Seth A; Danso, Michael; Lu, Dongrui R; Perkins Smith, Julia; Liu, Yuan; Tran, Lana; Anderson, Sibyl; and Campone, Mario, "VERITAC-2: A Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer." Future Oncology. 20, 32. 2447 - 2455. (2024).
https://digitalcommons.wustl.edu/oa_4/4563

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.